STI-571 in chronic myelogenous leukaemia

British Journal of Haematology

Volumn 119, Issue 1, 2002, Pages 15-24

  Tsao, Anne S ^a   Kantarjian, Hagop ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BCR ABL; Clinical trials; CML; Imatinib mesylate; Resistance

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; LEPTOMYCIN B; OROSOMUCOID; TROXACITABINE; VERAPAMIL;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; EDEMA; HUMAN; LIVER TOXICITY; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RASH; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; TUMOR CELLS, CULTURED;

EID: 0036400327     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03899.x     Document Type: Article

References (72)

1. Allan, N.C., Richards, S.M. & Shepherd, P.C. (1995) UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet, 345, 1392-1397.
2. Baccarani, M. (2001) American Society of Hematology Education Program Book. Non-Transplant Treatment Options for Patients with Newly Diagnosed Chronic Myelogenous Leukemia. American Society of Hematology Education Program Book, 1, 87-112. (www document) URL. http://www.asheducationbook.org.
3. Baccarani, M., Rosti, G., de Vivo, A., Bonifazi, F., Russo, D., Martinelli, G., Testoni, N., Amabile, M., Fiacchini, M., Montefusco, E., Saglio, G. Tura, S. & Italian Cooperative Study Group on Myeloid Leukemia (2002) A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood, 99, 1527-1535.
4. Barthe, C., Cony-Makhoul, P., Melo, J.V. & Mahon, J.R. (2001) Roots of clinical resistance to STI-571 cancer therapy. Science, 293, 2163.
5. Bartram, C.R., de Klein, A., Hagemeijer, A., van Agthoven, T., Geurts van Kessel, A., Bootsma. D., Grosveld. G., Ferguson-Smith, M.A., Davies, T. & Stone, M. (1983) Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature, 306, 277-280.
6. Bhatia, R. & Verfaillie, C.M. (1998) Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta 1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood, 91, 3414-3422.
7. Bonifazi, F., de Vivo, A., Rosti, G., Guilhot, F., Guilhot, J., Trabacchi, E., Hehlmann, R., Hochhaus, A., Shepherd, P.C., Steegmann, J.L., Kluin-Nelemans, H.C., Thaler, J., Simonsson, B., Louwagie, A.,Reiffers, J., Mahon, F.X., Montefusco, E., Alimena, G., Hasford, J., Richards, S., Saglio, G., Testoni, N., Martinelli, G., Tura, S. & Baccarani, M. European Study Group on Interferon in Chronic Myeloid Leukemia, Italian Cooperative Study Group on CML, France Intergroup of CML, German CML Study Group, UK Medical Research Council Working Party on CML, Spanish CML Study Group, Australian CML Study Group, Swedish CML Study Group (2001) Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood, 98, 3074-3081.
8. von Bubnoff, N., Schneller, F., Peschel, C. & Duyster, J. (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet, 359, 487-491.
9. Chronic Myeloid Leukemia Trialists' Collaborative Group (1997) Interferon-α versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. Journal of the National Cancer Institute, 89, 1616-1620.
10. Collins, S.J. (1986) Breakpoints on chromosome 9 and 22 in Philadelphia chromosome-positive chronic myelogenous leukemia (CML): amplification of rearranged c-abl oncogenes in CML blast crises. Journal of Clinical Investigation, 78, 1392-1396.
11. Collins, S.J. & Groudine, M.T. (1987) Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crises. Blood, 69, 893-898.
12. le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R. & Gambacorti-Passerini, C. (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood, 95, 1758-1766.
13. Donato, N., Wu, J., Albitar, M., Arlinghaus, R., Kantarjian, H. & Talpaz, M. (2001a) Multiple resistance mechanisms identified through studies of cell lines derived from chronic myelogenous leukemia patients progressing on STI-571 therapy. ASH, 3206 (Abstract). (WWW document). URL. http://www.(Abstract)s-on-line.com/(Abstract)s/HEM/search/results.asp?Num= 0%2E8109354.
14. Donato, N., Wu, J., Gallick, G., Arlinghaus, R. & Talpaz, M. (2001b) A dominant role for LYN Kinase in K562 cells selected for resistance to STI-571. ASH, 3487 (Abstract). (WWW document). URL. http://www.(Abstract)s-on-line.com/(Abstract)s/HEM/search/results.asp?Num= 0%2E1363139.
15. Donato, N., Wu, J., Lin, H., Arlinghaus, R., Albitar, M., Patek, S. & Talpaz, M. (2002) Novel STI-571 resistance mechanisms in Ph (+) leukemia revealed through analysis of cells derived from STI-571 resistant chronic myelogenous leukemia (CML) patients. AACR (WWW document). URL. http://aacr02.agora.com/planner/displayabstract.asp?presentationid=3104.
16. Dowding, C., Guo, A.P., Osterholz, J., Siczkowski, M., Goldman, J. & Gordon, M. (1991) Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood, 78, 499-505.
17. Druker, B.J. & International Randomized IFN vs. STI571 Study Group (IRIS) (2002) STI-571 (Gleevac/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study. ASCO, 1 Abstract (WWW document) URL. http://www.asco.org/asco/ascoMainConstructor/1,47468,_12|002324|00-29|00A| 00-18|002002|00-19|001,00.asp.
18. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J. & Lydon, N.B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nature Medicine, 2, 561-566.
19. Druker, B.J., Sawyers, C.L., Capdeville, R., Ford, J., Baccarani, M. & Goldman, J. (2001a) Chronic myelogenous leukemia. American Society for Hematology Education Book, 1, 87-112. (WWW document) URL. http://www.asheducationbook.org.
20. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. (2001b) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 1031-1037.
21. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D., Reese, S., Ford, J., Capdeville, R. & Talpaz, M. (2001c) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crises of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine, 344, 1038-1042.
22. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R. & Kantarjian, H. (1999) Mechanisms of disease: The biology of chronic myeloid leukemia. New England Journal of Medicine, 341, 164-172.
23. Gambacorti-Passerini, C., Barni, R., le Coutre, P., Zucchetti, M., Cabrita, G., Cleris, L., Rossi, F., Gianazza, E., Brueggen, J., Cozens, R., Pioltelli, P., Pogliani, E., Corneo, G., Formelli, F. & D'Incalci, M. (2000) Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the abl inhibitor STI-571. Journal of the National Cancer Institute, 92, 1641-1650.
24. Gesbert, F. & Griffin, J.D. (2000) Bcr/Abl activates transcription of Bcl-X gene through STAT 5. Blood, 96, 2269-2276.
25. Gesbert, F., Sellers, W.R., Signoretti, S., Loda, M. & Griffin, J.D. (2000) BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. Journal of Biological Chemistry, 275, 39223-39230.
26. Goldman, J.M., Baughan, A.S., McCarthy, D.M., Worsley, A.M., Hows, J.M., Gordon-Smith, E.C., Catovsky, D., Batchelor, J.R., Goolden, A.W. & Galton, D.A. (1982) Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet, 2, 623-625.
27. Gordon, M.Y., Dowding, C.R., Riley, G.P., Goldman, J.M. & Greaves, M.F. (1987) Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature, 328, 342-344.
28. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. & Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876-880.
29. Griffin, J. (2001) The biology of signal transduction inhibition: basic science to novel therapies. Seminars in Oncology, 28, 3-8.
30. Griffin, J. (2002) Resistance to targeted therapy in leukaemia. Lancet, 359, 458-459.
31. Groffen, J., Stephenson, J.R., Heisterkamp, N., de Klein, A., Bartram, C.R. & Grosveld, G. (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell, 36, 93-99.
32. Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.L., Maloisel, F., Bouabdallah, R., Guyotat, D., Cheron, N., Nicolini, F., Abgrall, J.F. & Tanzer, J. (1997) Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. New England Journal of Medicine, 337, 223-239.
33. Hastings, P.J., Bull, H.J., Klump, J.R. & Rosenberg, S.M. (2000) Adaptive amplification: an inducible chromosomal instability mechanism. Cell, 103, 723-731.
34. Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H.J., Pralle, H., Hossfeld, D.K., Queisser, W., Loffler, H., Heinze, B. & Georgii, A. (1993) Randomized comparison of busulphan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood, 82, 398-407.
35. Heisterkamp, N., Stephenson, J.R., Groffen, J., Hansen, P.F., de Klein, A., Bartram, C.R. & Grosveld, G. (1983) Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature, 306, 239-242.
36. Hochhaus, A., Kreil, S., Corbin, A., La Rosee, P., Lahaye, T., Berger, U., Cross, N.C., Linkesch, W., Druker, B.J., Hehlmann, R., Gambacorti-Passerini, C., Corneo, G. & D'Incalci, M. (2001) Roots of clinical resistance to STI-571 cancer therapy. Science, 293, 2163.
37. Hofmann, W.K., Jones, L.C., Lemp, N.A., de Vos, S., Gschaidmeier, H., Hoelzer, D., Ottmann, O.G. & Koeffler, H.P. (2002a) Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood, 99, 1860-1862.
38. Hofmann, W.K., de Vos, S., Elashoff, D., Gschaidmeier, H., Hoelzer, D., Koeffler, P. & Ottmann, O.G. (2002b) Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet, 359, 481-486.
39. Horowitz, M.M., Rowlings, P.A. & Passweg, J.R. (1996) Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplantation, 17, S5-S6.
40. Jorgensen, H.G., Elliott, M.A., Allan, E.K., Carr, C.E., Holyoake, T.L. & Smith, K.D. (2002) α1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood, 99, 713-715.
41. Kalidas, M., Kantarjian, H. & Talpaz, M. (2001) Chronic Myelogenous Leukemia. JAMA, 286, 895-898.
42. Kantarjian, H.M. & Talpaz, M. (2001) Imatinib Mesylate. Clinical results in philadelphia chromosome-positive leukemias. Seminars in Oncology, 28, 9-18.
43. Kantarjian, H.M., Smith, T.L., O'Brien, S., Beran, M., Pierce, S. & Talpaz, M. (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Annals of Internal Medicine, 122, 254-261.
44. Kantarjian, H.M., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M. & Druker, B. (2002a) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New England Journal of Medicine, 346, 645-652.
45. Kantarjian, H.M., Jorge, C., O'Brien, S., Giles, F., Thomas, D., Faderl, S., Garcia-Manero, G., Rios, M., Letvak, L., Bochinski, K., Shan, J. & Talpaz, M. (2002b) High rates of early major and complete cytogenetic responses with imatinib mesylate therapy given at 400 mg or 800 mg orally daily in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. ASCO, Abstract 1043. (WWW document). URL. http://www.asco.org/asco/ascoMainConstructor/1,47468,_12|002324|00-29|00A| 00-18|002002|00-19|001043,00.asp.
46. Kantarjian, H.M., Cortes, J., O'Brien, S., Giles, F.J., Albitar, M., Rios, M., Shan, J., Faderl, S., Garcia-Manero, G., Thomas, D.A., Resta, D. & Talpaz, M. (2002c) Imatinib mesylate (STI571) for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood, 99, 3547-3553.
47. Kloke, O., Niederle, N., Qui, J.Y., Wandl, U., Moritz, T., Nagel-Hiemke, M., Hawig, I., Opalka, B., Seeber, S. & Becher, R. (1993) Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. British Journal of Hematology, 83, 399-403.
48. Kurzrock, R., Gutterman, J.U. & Talpaz, M. (1988) The molecular genetics of Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 319, 990-998.
49. Laneuville, P., Sun, G., Timm, M. & Vekemans, M. (1992) Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. Blood, 80, 1788-1797.
50. Mahon, F.X., Deininger, M.W., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J.M. & Melo, J.V. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 96, 1070-1079.
51. Nowell, P.C. & Hungerford, D.A. (1960) A minute chromosome in human chronic granulocytic leukemia. Science, 132, 1497.
52. Ohnishi, K., Ohno, R., Tomonaga, M., Kamada, N., Onozawa, K., Kuramoto, A., Dohy, H., Mizoguchi, H., Miyawaki, S. & Tsubaki, K. (1995) A randomized trial comparing interferon-alpha with busulphan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood, 86, 906-916.
53. Okuda, K., Golub, T.R., Gilliland, D.G. & Griffin, J.D. (1996) p210 BCR/ABL, p190 BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene, 13, 1147-1152.
54. Ozer, H., George, S.L., Schiffer, C.A., Rao, K., Rao, P.N., Wurster-Hill, D.H., Arthur, D.D., Powell, B., Gottlieb, A. & Peterson, B.A. (1993) Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival. Cancer and Leukemia Group B Study 8583. Blood, 82, 2975-2984.
55. Priebe, W., Evrony, G., Fokt, I., Talpaz, M. & Donato, N. (2002) WP744, a novel anthracycline with enhanced apoptotic and anti-proliferative activity on STI-571 resistant leukemic cells: Design, synthesis, and evaluation. AACR abstract 4197. (WWW document) URL. http://aacr02.agora.com/planner/displayabstract.asp?presentationid=3106.
56. Raitano, A.B., Whang, Y.E. & Sawyers, C.L. (1997) Signal transduction by wild-type and leukemogenic Abl proteins. Biochimica et Biophysica Acta, 1333, F201-F216.
57. Rowley, J.D. (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243, 290-293.
58. Savage, D.G. & Antman, K.H. (2002) Imatinib Mesylate - A new oral targeted therapy. New England Journal of Medicine, 346, 683-693.
59. Sawyers, C.L. (1999) Medical Progress. Chronic Myeloid Leukemia. New England Journal of Medicine, 340, 1330-1340.
60. Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, O.G., Schiffer, C.A., Talpaz, M., Guilhot, F., Deininger, M.W., Fischer, T., O'Brien, S.G., Stone, R.M., Gambacorti-Passerini, C.B., Russell, N.H., Reiffers, J.J., Shea, T.C., Chapuis, B., Coutre, S., Tura, S., Morra, E., Larson, R.A., Saven, A., Peschel, C., Gratwohl, A., Mandelli, F., Ben-Am, M., Gathmann, I., Capdeville, R., Paquette, R.L. & Druker, B.J. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chornic myelogenous leukemia in myeloid blast crises: results of a phase II study. Blood, 99, 3530-3539.
61. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B. & Kuriyan, J. (2000) Structural mechanisms for STI-571 inhibition of abelson tyrosine kinase. Science, 289, 1938-1942.
62. Shtivelman, E., Lifshitz, B., Gale, R.P. & Canaani, E. (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature, 315, 550-554.
63. Talpaz, M., McCredie, K.B., Mavligit, G.M. & Gutterman, J.U. (1983) Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood, 62, 689-692.
64. Talpaz, M., Kantarjian, H.M., McCredie, K., Trujillo, J.M., Keating, M.J. & Gutterman, J.U. (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. New England Journal of Medicine, 314, 1065-1069.
65. Talpaz, M., Silver, R.T., Druker, B.J., Goldman, J.M., Gambacorti-Passerini, C., Guilhot, F., Schiffer, C.A., Fischer, T., Deininger, M.W., Lennard, A.L., Hochhaus, A., Ottmann, O.G., Gratwohl, A., Baccarani, M., Stone, R., Tura, S., Mahon, F.X., Fernandes-Reese, S., Gathmann, R., Capdeville, R., Kantarjian, H.M. & Sawyers, C.L. (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 99, 1928-1937.
66. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New England Journal of Medicine, 330, 820-825.
67. Tipping, A.J., Mahon, F.X., Lagarde, V., Goldman, J.M. & Melo, J.V. (2001) Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood, 98, 3864-3867.
68. Verweij, J., Judson, I. & van Oosterom, A. (2001) STI571 a magic bullet? European Journal of Cancer, 37, 1816-1819.
69. Vigneri, P. & Wang, J.Y. (2001) Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nature Medicine, 7, 228-234.
70. Weisberg, E. & Griffin, J.D. (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood, 95, 3498-3505.
71. Wu, J., Talpaz, M., Gallick, G., Lin, H., Arlinhaus, R. & Donato, N. (2002) Lyn kinase activation and overexpression in K562 cells selected for resistance to BCR-ABL kinase inhibitor (STI-571, Gleevec, imatinib mesylate). AACR, abstract 2101. (WWW document). URL. http://aacr02.agora.com/planner/displayabstract.asp?presentationid=6875.
72. Wu, S.Q., Voelkerding, K.V., Sabatini, L., Chen, X.R., Huang, J. & Meisner, L.F. (1995) Extensive amplification of bcr/abl fusion genes clustered on three marker chromosomes in human leukemic cell line K-562. Leukemia, 9, 858-862.